+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Severe Acute Respiratory Syndrome (SARS) Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Severe Acute Respiratory Syndrome (SARS)

  • ID: 4629657
  • Report
  • September 2018
  • Region: Global
  • 65 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Abhelix LLC
  • Biotron Ltd
  • CEL-SCI Corp
  • GeneCure LLC
  • Gilead Sciences Inc
  • MORE
Severe Acute Respiratory Syndrome (SARS) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Severe Acute Respiratory Syndrome (SARS) Infection pipeline products.

Report Description

The Severe Acute Respiratory Syndrome (SARS) Infection pipeline guide presents complete overview of drugs currently being developed for Severe Acute Respiratory Syndrome (SARS) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Severe Acute Respiratory Syndrome (SARS) Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Severe Acute Respiratory Syndrome (SARS) Infection pipeline candidates is included.

Major companies participating in therapeutic development of Severe Acute Respiratory Syndrome (SARS) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Severe Acute Respiratory Syndrome (SARS) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Severe Acute Respiratory Syndrome (SARS) Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Severe Acute Respiratory Syndrome (SARS) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Severe Acute Respiratory Syndrome (SARS) Infection pipeline report includes
  • Panorama of Severe Acute Respiratory Syndrome (SARS) Infection pipeline markets including statistics on therapeutic drugs and companies involved
  • Severe Acute Respiratory Syndrome (SARS) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
  • Severe Acute Respiratory Syndrome (SARS) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Severe Acute Respiratory Syndrome (SARS) Infection pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Severe Acute Respiratory Syndrome (SARS) Infection pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Severe Acute Respiratory Syndrome (SARS) Infection pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Severe Acute Respiratory Syndrome (SARS) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Abhelix LLC
  • Biotron Ltd
  • CEL-SCI Corp
  • GeneCure LLC
  • Gilead Sciences Inc
  • MORE
I. Key Findings

1. Companies Investing in Severe Acute Respiratory Syndrome (SARS) Infection Pipeline include-
Number of Companies with Severe Acute Respiratory Syndrome (SARS) Infection projects in pre-clinical Development-
Number of Companies with Severe Acute Respiratory Syndrome (SARS) Infection projects in Clinical Development-
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Companies based in Americas
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Companies based in Europe
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Companies based in Asia Pacific
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Agents in Clinical Development stage
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Severe Acute Respiratory Syndrome (SARS) Infection Pipeline agents

II. Insights into Severe Acute Respiratory Syndrome (SARS) Infection Pipeline -

1. Disease Overview
Introduction to Severe Acute Respiratory Syndrome (SARS) Infection
Symptoms and Causes of Severe Acute Respiratory Syndrome (SARS) Infection
Treatment or Prevention Options for Severe Acute Respiratory Syndrome (SARS) Infection
Other Details
2. Phase wise Pipeline Compounds
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline- Phase 1 stage Drugs
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline- Phase 2 stage Drugs
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline- Phase 3 stage Drugs
Severe Acute Respiratory Syndrome (SARS) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Compounds
4. Severe Acute Respiratory Syndrome (SARS) Infection Pipeline by Mechanism of Action

III. Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Compound Details
  • TVB-3567
  • Drug for MERS ans SERS
  • CSW-1
  • Small Molecule fo SARS (E protein)
  • CEL-1000
  • SARS vaccine
  • GS-5734
  • monoclonal antibody for SARS
  • SARS VLP vaccine
  • Poly-ICLC
  • Antivaral for SARS
  • D3252
Drug Details

1. Snapshot-
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Company Briefs
  • 3-V Biosciences Inc
  • Abhelix LLC
  • Autoimmune Technologies LLC
  • Biotron Ltd
  • CEL-SCI Corp
  • GeneCure LLC
  • Gilead Sciences Inc
  • MassBiologics
  • Novavax Inc
  • Oncovir Inc
  • Phelix Therapeutics LLC
  • Sanofi
V. Latest News and Developments in Global Severe Acute Respiratory Syndrome (SARS) Infection Pipeline Market

VI. Appendix
1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability"
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3-V Biosciences Inc
  • Abhelix LLC
  • Autoimmune Technologies LLC
  • Biotron Ltd
  • CEL-SCI Corp
  • GeneCure LLC
  • Gilead Sciences Inc
  • MassBiologics
  • Novavax Inc
  • Oncovir Inc
  • Phelix Therapeutics LLC
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll